checkAd

XPhyto Completes Strategic Acquisition of 3a-diagnostics GmbH

The acquisition positions XPhyto to be a leading Biosensor producer integrating thin film technology with 3a-diagnostics biosensor technologyThe acquisition of 3a, a German-based rapid point-of-care diagnostics firm adds IP and a deeply experienced …

  • The acquisition positions XPhyto to be a leading Biosensor producer integrating thin film technology with 3a-diagnostics biosensor technology
  • The acquisition of 3a, a German-based rapid point-of-care diagnostics firm adds IP and a deeply experienced scientific expertise to XPhyto
  • Gains technical and business synergies
  • Secures XPhyto a near-term infectious disease biosensor portfolio and related Intellectual Property

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / December 6, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to announce that the acquisition of 3a-diagnostics GmbH ("3a"), first announced July 20, 2021, is now complete.

"The strategic acquisition of 3a is a transformative step in XPhyto's commercial strategy," said Peter Damouni, XPhyto director. "The integration of a highly innovative European biosensor development company places XPhyto at the forefront of the rapid point-of-care test industry, an explosive and technology driven sector. This transaction is the second acquisition since going public in August 2019. XPhyto completed the takeover of Vektor Pharma TF GmbH in September 2019. The corporate strategy of acquiring high-tech biotechnology and pharma companies showcases the potential growth acceleration and synergies for XPhyto's biosensors, diagnostics and drug delivery portfolios."

3a is a research-based biotechnology company located Southeast of Stuttgart, Germany, specializing in the development, production and marketing of point-of-care (PoC) test systems. 3a has developed and patented a pipeline of oral biosensor screening tests for bacterial and viral infectious diseases, including stomatitis, periimplantitis, periodontitis, group A strep, and influenza A. The company has developed a high-throughput biosensor screening platform for rapid identification of new biosensor targets. 3a has also received grant funding from the German Federal Ministry of Education and Research for the development of real-time, low-cost and easy-to-use oral screening tests for the rapid detection of influenza A variants that are high-risk pandemic threats such as H1N1 and H5N1.

Seite 1 von 4


Nachrichtenagentur: Accesswire
06.12.2021, 09:05  |  114   |   |   

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

XPhyto Completes Strategic Acquisition of 3a-diagnostics GmbH The acquisition positions XPhyto to be a leading Biosensor producer integrating thin film technology with 3a-diagnostics biosensor technologyThe acquisition of 3a, a German-based rapid point-of-care diagnostics firm adds IP and a deeply experienced …

Nachrichten des Autors

Titel
Titel
Titel
Titel